RDEB
29 May 2021

A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa

 Mol Ther Nucleic Acids. 2021 May 29;25:237-250. doi: 10.1016/j.omtn.2021.05.015. PMID: 34458008; PMCID: PMC8368800. A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa […]
26 April 2023

A Case of Recessive Dystrophic Epidermolysis Bullosa Associated Colitis

JPGN Rep. 2023 Apr 26;4(2):e313. doi: 10.1097/PG9.0000000000000313. PMID: 37200727; PMCID: PMC10187860. A Case of Recessive Dystrophic Epidermolysis Bullosa Associated Colitis Authors: Katelyn McCann 1, Karen Wiss 1 2, Jeffrey Covington 3, Vanessa Laffert 1, Kerri B Gosselin 1 Affiliation: […]
24 May 2023

Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa

Cells. 2023 May 24;12(11):1468. doi: 10.3390/cells12111468. PMID: 37296590; PMCID: PMC10252830. Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment […]
1 June 2023

Generation and characterization of induced pluripotent stem cell lines from two patients with recessive dystrophic epidermolysis Bullosa

Stem Cell Res. 2023 Jun;69:103104. doi: 10.1016/j.scr.2023.103104. Epub 2023 Apr 24. PMID: 37148821. Generation and characterization of induced pluripotent stem cell lines from two patients with […]
1 June 2023

Success of dupilumab in itchy recessive dystrophic epidermolysis bullosa of non-pruriginosa subtype

J Dermatol. 2023 Jun;50(6):837-842. doi: 10.1111/1346-8138.16729. Epub 2023 Jan 24. PMID: 36694424. Success of dupilumab in itchy recessive dystrophic epidermolysis bullosa of non-pruriginosa subtype Authors: Xue-Ge […]
4 July 2023

ABSTRACT: Compassionate use of topical beremagene geperpavec (B-VEC) for the treatment of recurrent cicatrizing conjunctivitis in a patient with dystrophic epidermolysis bullosa

Keywords: B-VEC, Krystal, Opthalmology, Gene therapy
11 October 2023

CRISPR/Cas9 Based Non-viral Gene Editing Therapy for Topical Treatment ofRecessive Dystrophic Epidermolysis Bullosa

Molecular Therapy: Methods & Clinical Development – JOURNAL PRE-PROOF CRISPR/Cas9 Based Non-viral Gene Editing Therapy for Topical Treatment ofRecessive Dystrophic Epidermolysis Bullosa Authors: Xianqing Wang, Xi […]